Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium

Daniel W Brookes, Matthew Coates, Heather Allen, Leah Daly, Samuel Constant, Song Huang, Mark Hows, Amanda Davis, Lindsey Cass, John Ayrton, Ian Knowles, Pete Strong, Garth Rapeport, Kazuhiro Ito
  • British Journal of Pharmacology, May 2018, Wiley
  • DOI: 10.1111/bph.14221

Anti-viral efefcts of a Novel RSV polymerase inhibitor, PC786, on primary airrway epithelial cells.

What is it about?

Effective anti‐respiratory syncytial virus (RSV) agents are still not available for clinical use. We have investigated the effects of late therapeutic intervention (clinical treatment senario) with a novel inhaled RSV polymerase inhibitor, PC786, on RSV infection in human airway epithelium. Late therapeutic intervention with the RSV polymerase inhibitor, PC786, reduced the viral burden quickly in human airway epithelium. Thus, PC786 demonstrates the potential to be an effective therapeutic agent to treat active RSV infection.

Why is it important?

Effective anti‐respiratory syncytial virus (RSV) agents are still not available for clinical use and major recent approch is virus entry inhibition for prophylactic use. This new approach with polymerase inhibitor enables to inhibit RSV replication even after virus inbfection is established. In addition, this molecule is optimised for inhalation, leading limited systemic efefcts and high local exposure for more potent anti-viral effect and less mutation induction.


Dr Kazuhiro Ito

We set up 3D air-liquid interfecase cultured airway epithelial cells as more translational model as RSV does not replicate well in animals as this is human respiratory virus. This system is useful for different intervention (inhalation, oral mimic, daily treatment, biomarker analysis etc) .

Read Publication

The following have contributed to this page: Dr Kazuhiro Ito

In partnership with: